Multicenter retrospective study of anti-PD-1 consolidation in patients with high risk of relapse after autoSCT for Hodgkin lymphoma

Consolidation therapy is an emerging strategy for patients with relapsed or refractory Hodgkin lymphoma (RR-HL) at high risk of failing salvage autologous stem cell transplantation (autoHSCT). A multicenter retrospective study in Italy evaluated anti-PD-1 consolidation for these patients. At a median follow-up of 25.8 months post-autoSCT the median progression-free survival was 42.6 months, with 2-years PFS and overall survival rates 79% and 87%, respectively. The authors conclude that post-autoSCT consolidation with anti-PD-1 is feasible and effective.